nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—MTHFR—type 2 diabetes mellitus	0.123	0.455	CbGaD
Methotrexate—ABCC2—type 2 diabetes mellitus	0.107	0.394	CbGaD
Methotrexate—SLC16A1—Nateglinide—type 2 diabetes mellitus	0.0428	0.0992	CbGbCtD
Methotrexate—ALB—type 2 diabetes mellitus	0.0412	0.152	CbGaD
Methotrexate—SLCO1B3—Pioglitazone—type 2 diabetes mellitus	0.0316	0.0731	CbGbCtD
Methotrexate—SLCO1B3—Valsartan—type 2 diabetes mellitus	0.0257	0.0596	CbGbCtD
Methotrexate—ABCC4—Nateglinide—type 2 diabetes mellitus	0.0206	0.0477	CbGbCtD
Methotrexate—SLCO1B1—Repaglinide—type 2 diabetes mellitus	0.0203	0.0471	CbGbCtD
Methotrexate—SLCO1B1—Pioglitazone—type 2 diabetes mellitus	0.0184	0.0426	CbGbCtD
Methotrexate—ABCC3—Glyburide—type 2 diabetes mellitus	0.0182	0.0421	CbGbCtD
Methotrexate—SLCO1A2—Tolbutamide—type 2 diabetes mellitus	0.0174	0.0402	CbGbCtD
Methotrexate—SLCO1B1—Rosiglitazone—type 2 diabetes mellitus	0.017	0.0393	CbGbCtD
Methotrexate—SLCO1B1—Valsartan—type 2 diabetes mellitus	0.015	0.0347	CbGbCtD
Methotrexate—SLCO1B3—Losartan—type 2 diabetes mellitus	0.0148	0.0342	CbGbCtD
Methotrexate—SLC22A7—Glyburide—type 2 diabetes mellitus	0.0142	0.0329	CbGbCtD
Methotrexate—ALB—Gliclazide—type 2 diabetes mellitus	0.0118	0.0274	CbGbCtD
Methotrexate—SLC22A6—Chlorpropamide—type 2 diabetes mellitus	0.0118	0.0274	CbGbCtD
Methotrexate—ABCC1—Glyburide—type 2 diabetes mellitus	0.0112	0.0259	CbGbCtD
Methotrexate—ALB—Repaglinide—type 2 diabetes mellitus	0.0111	0.0258	CbGbCtD
Methotrexate—SLC22A6—Tolbutamide—type 2 diabetes mellitus	0.0105	0.0244	CbGbCtD
Methotrexate—SLCO1A2—Glyburide—type 2 diabetes mellitus	0.00997	0.0231	CbGbCtD
Methotrexate—ALB—Rosiglitazone—type 2 diabetes mellitus	0.00929	0.0215	CbGbCtD
Methotrexate—SLC22A6—Nateglinide—type 2 diabetes mellitus	0.00896	0.0207	CbGbCtD
Methotrexate—SLCO1B1—Losartan—type 2 diabetes mellitus	0.00861	0.0199	CbGbCtD
Methotrexate—ABCC2—Glyburide—type 2 diabetes mellitus	0.00827	0.0191	CbGbCtD
Methotrexate—ALB—Valsartan—type 2 diabetes mellitus	0.00821	0.019	CbGbCtD
Methotrexate—ABCB1—Linagliptin—type 2 diabetes mellitus	0.00817	0.0189	CbGbCtD
Methotrexate—ALB—Nateglinide—type 2 diabetes mellitus	0.00763	0.0177	CbGbCtD
Methotrexate—ABCG2—Glyburide—type 2 diabetes mellitus	0.00748	0.0173	CbGbCtD
Methotrexate—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.00728	0.0169	CbGbCtD
Methotrexate—SLC22A6—Glyburide—type 2 diabetes mellitus	0.00605	0.014	CbGbCtD
Methotrexate—SLC22A6—Losartan—type 2 diabetes mellitus	0.00553	0.0128	CbGbCtD
Methotrexate—ATIC—pes—type 2 diabetes mellitus	0.00527	0.103	CbGeAlD
Methotrexate—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.00527	0.0122	CbGbCtD
Methotrexate—ALB—Glyburide—type 2 diabetes mellitus	0.00515	0.0119	CbGbCtD
Methotrexate—ALB—Losartan—type 2 diabetes mellitus	0.00471	0.0109	CbGbCtD
Methotrexate—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00362	0.00838	CbGbCtD
Methotrexate—ABCB1—Glyburide—type 2 diabetes mellitus	0.0027	0.00624	CbGbCtD
Methotrexate—ATIC—leg—type 2 diabetes mellitus	0.00269	0.0526	CbGeAlD
Methotrexate—ABCB1—Losartan—type 2 diabetes mellitus	0.00247	0.00571	CbGbCtD
Methotrexate—ATIC—hindlimb—type 2 diabetes mellitus	0.0024	0.047	CbGeAlD
Methotrexate—MTHFR—artery—type 2 diabetes mellitus	0.00109	0.0214	CbGeAlD
Methotrexate—FOLR1—nephron tubule—type 2 diabetes mellitus	0.00101	0.0197	CbGeAlD
Methotrexate—Tetrahydrofolic acid—MTR—type 2 diabetes mellitus	0.000997	0.378	CrCbGaD
Methotrexate—FOLR1—kidney—type 2 diabetes mellitus	0.000885	0.0173	CbGeAlD
Methotrexate—FOLR1—cortex of kidney—type 2 diabetes mellitus	0.000862	0.0169	CbGeAlD
Methotrexate—FPGS—islet of Langerhans—type 2 diabetes mellitus	0.00073	0.0143	CbGeAlD
Methotrexate—SLC19A1—adipose tissue—type 2 diabetes mellitus	0.000699	0.0137	CbGeAlD
Methotrexate—GGH—nephron tubule—type 2 diabetes mellitus	0.000669	0.0131	CbGeAlD
Methotrexate—FPGS—retina—type 2 diabetes mellitus	0.000625	0.0122	CbGeAlD
Methotrexate—ATIC—retina—type 2 diabetes mellitus	0.000604	0.0118	CbGeAlD
Methotrexate—SLCO4C1—nephron tubule—type 2 diabetes mellitus	0.000593	0.0116	CbGeAlD
Methotrexate—GGH—kidney—type 2 diabetes mellitus	0.000588	0.0115	CbGeAlD
Methotrexate—GGH—pancreas—type 2 diabetes mellitus	0.000584	0.0114	CbGeAlD
Methotrexate—GGH—cortex of kidney—type 2 diabetes mellitus	0.000573	0.0112	CbGeAlD
Methotrexate—ABCC11—liver—type 2 diabetes mellitus	0.000536	0.0105	CbGeAlD
Methotrexate—GGH—adipose tissue—type 2 diabetes mellitus	0.00053	0.0104	CbGeAlD
Methotrexate—SLCO4C1—kidney—type 2 diabetes mellitus	0.000521	0.0102	CbGeAlD
Methotrexate—ATIC—cardiovascular system—type 2 diabetes mellitus	0.000511	0.01	CbGeAlD
Methotrexate—SLCO4C1—cortex of kidney—type 2 diabetes mellitus	0.000508	0.00994	CbGeAlD
Methotrexate—FPGS—cortex of kidney—type 2 diabetes mellitus	0.000503	0.00986	CbGeAlD
Methotrexate—ATIC—kidney—type 2 diabetes mellitus	0.0005	0.00979	CbGeAlD
Methotrexate—ATIC—pancreas—type 2 diabetes mellitus	0.000497	0.00972	CbGeAlD
Methotrexate—SLC19A1—liver—type 2 diabetes mellitus	0.00049	0.0096	CbGeAlD
Methotrexate—TYMS—Bortezomib—Nateglinide—type 2 diabetes mellitus	0.000468	1	CbGdCrCtD
Methotrexate—FPGS—adipose tissue—type 2 diabetes mellitus	0.000466	0.00912	CbGeAlD
Methotrexate—SLC22A11—nephron tubule—type 2 diabetes mellitus	0.000459	0.00899	CbGeAlD
Methotrexate—Leucovorin—ABCC2—type 2 diabetes mellitus	0.000458	0.174	CrCbGaD
Methotrexate—PGD—islet of Langerhans—type 2 diabetes mellitus	0.000456	0.00893	CbGeAlD
Methotrexate—ATIC—adipose tissue—type 2 diabetes mellitus	0.000451	0.00882	CbGeAlD
Methotrexate—SLCO3A1—retina—type 2 diabetes mellitus	0.000442	0.00865	CbGeAlD
Methotrexate—SLC22A6—nephron tubule—type 2 diabetes mellitus	0.000433	0.00847	CbGeAlD
Methotrexate—SLCO1C1—kidney—type 2 diabetes mellitus	0.000416	0.00814	CbGeAlD
Methotrexate—DHFR—retina—type 2 diabetes mellitus	0.000406	0.00794	CbGeAlD
Methotrexate—SLC22A11—kidney—type 2 diabetes mellitus	0.000404	0.0079	CbGeAlD
Methotrexate—AOX1—islet of Langerhans—type 2 diabetes mellitus	0.000402	0.00787	CbGeAlD
Methotrexate—SLC22A7—kidney—type 2 diabetes mellitus	0.000394	0.00771	CbGeAlD
Methotrexate—SLC22A11—cortex of kidney—type 2 diabetes mellitus	0.000393	0.0077	CbGeAlD
Methotrexate—PGD—retina—type 2 diabetes mellitus	0.00039	0.00763	CbGeAlD
Methotrexate—TYMS—nephron tubule—type 2 diabetes mellitus	0.000386	0.00755	CbGeAlD
Methotrexate—SLC22A7—cortex of kidney—type 2 diabetes mellitus	0.000384	0.00751	CbGeAlD
Methotrexate—DHFR—nephron tubule—type 2 diabetes mellitus	0.000382	0.00748	CbGeAlD
Methotrexate—MTHFR—cardiovascular system—type 2 diabetes mellitus	0.00038	0.00743	CbGeAlD
Methotrexate—SLC46A1—liver—type 2 diabetes mellitus	0.000378	0.0074	CbGeAlD
Methotrexate—SLCO1C1—adipose tissue—type 2 diabetes mellitus	0.000375	0.00733	CbGeAlD
Methotrexate—GGH—liver—type 2 diabetes mellitus	0.000372	0.00728	CbGeAlD
Methotrexate—SLC22A6—cortex of kidney—type 2 diabetes mellitus	0.00037	0.00725	CbGeAlD
Methotrexate—PGD—nephron tubule—type 2 diabetes mellitus	0.000367	0.00719	CbGeAlD
Methotrexate—SLCO3A1—kidney—type 2 diabetes mellitus	0.000366	0.00716	CbGeAlD
Methotrexate—SLC16A1—retina—type 2 diabetes mellitus	0.000364	0.00713	CbGeAlD
Methotrexate—SLCO3A1—cortex of kidney—type 2 diabetes mellitus	0.000356	0.00697	CbGeAlD
Methotrexate—DHFR—cardiovascular system—type 2 diabetes mellitus	0.000343	0.00672	CbGeAlD
Methotrexate—Folic Acid—MTHFR—type 2 diabetes mellitus	0.000341	0.129	CrCbGaD
Methotrexate—Tetrahydrofolic acid—MTHFR—type 2 diabetes mellitus	0.000341	0.129	CrCbGaD
Methotrexate—DHFR—kidney—type 2 diabetes mellitus	0.000336	0.00657	CbGeAlD
Methotrexate—MTHFR—adipose tissue—type 2 diabetes mellitus	0.000335	0.00656	CbGeAlD
Methotrexate—TYMS—cortex of kidney—type 2 diabetes mellitus	0.00033	0.00646	CbGeAlD
Methotrexate—PGD—cardiovascular system—type 2 diabetes mellitus	0.00033	0.00646	CbGeAlD
Methotrexate—SLCO4C1—liver—type 2 diabetes mellitus	0.00033	0.00645	CbGeAlD
Methotrexate—SLCO3A1—adipose tissue—type 2 diabetes mellitus	0.00033	0.00645	CbGeAlD
Methotrexate—DHFR—cortex of kidney—type 2 diabetes mellitus	0.000327	0.0064	CbGeAlD
Methotrexate—FPGS—liver—type 2 diabetes mellitus	0.000327	0.0064	CbGeAlD
Methotrexate—AOX1—nephron tubule—type 2 diabetes mellitus	0.000324	0.00633	CbGeAlD
Methotrexate—PGD—kidney—type 2 diabetes mellitus	0.000323	0.00632	CbGeAlD
Methotrexate—SLCO1B3—liver—type 2 diabetes mellitus	0.00032	0.00627	CbGeAlD
Methotrexate—ATIC—liver—type 2 diabetes mellitus	0.000316	0.00619	CbGeAlD
Methotrexate—PGD—cortex of kidney—type 2 diabetes mellitus	0.000314	0.00615	CbGeAlD
Methotrexate—SLC16A1—cardiovascular system—type 2 diabetes mellitus	0.000308	0.00603	CbGeAlD
Methotrexate—TYMS—adipose tissue—type 2 diabetes mellitus	0.000306	0.00598	CbGeAlD
Methotrexate—DHFR—adipose tissue—type 2 diabetes mellitus	0.000303	0.00592	CbGeAlD
Methotrexate—SLC16A1—kidney—type 2 diabetes mellitus	0.000301	0.0059	CbGeAlD
Methotrexate—Tetrahydrofolic acid—ABCC2—type 2 diabetes mellitus	0.000295	0.112	CrCbGaD
Methotrexate—SLCO1B1—kidney—type 2 diabetes mellitus	0.000293	0.00574	CbGeAlD
Methotrexate—PGD—adipose tissue—type 2 diabetes mellitus	0.000291	0.00569	CbGeAlD
Methotrexate—AOX1—kidney—type 2 diabetes mellitus	0.000284	0.00557	CbGeAlD
Methotrexate—AOX1—pancreas—type 2 diabetes mellitus	0.000282	0.00553	CbGeAlD
Methotrexate—ABCC3—kidney—type 2 diabetes mellitus	0.000278	0.00544	CbGeAlD
Methotrexate—AOX1—cortex of kidney—type 2 diabetes mellitus	0.000277	0.00542	CbGeAlD
Methotrexate—ABCC10—kidney—type 2 diabetes mellitus	0.000277	0.00542	CbGeAlD
Methotrexate—SLC16A1—adipose tissue—type 2 diabetes mellitus	0.000272	0.00532	CbGeAlD
Methotrexate—ABCC10—cortex of kidney—type 2 diabetes mellitus	0.00027	0.00528	CbGeAlD
Methotrexate—ABCC4—nephron tubule—type 2 diabetes mellitus	0.000261	0.00511	CbGeAlD
Methotrexate—SLC22A8—nephron tubule—type 2 diabetes mellitus	0.000259	0.00507	CbGeAlD
Methotrexate—AOX1—adipose tissue—type 2 diabetes mellitus	0.000256	0.00502	CbGeAlD
Methotrexate—SLC22A11—liver—type 2 diabetes mellitus	0.000255	0.005	CbGeAlD
Methotrexate—ABCC2—nephron tubule—type 2 diabetes mellitus	0.000253	0.00495	CbGeAlD
Methotrexate—ABCC3—adipose tissue—type 2 diabetes mellitus	0.000251	0.00491	CbGeAlD
Methotrexate—ABCC10—adipose tissue—type 2 diabetes mellitus	0.000249	0.00488	CbGeAlD
Methotrexate—SLC22A7—liver—type 2 diabetes mellitus	0.000249	0.00488	CbGeAlD
Methotrexate—SLCO1A2—kidney—type 2 diabetes mellitus	0.000239	0.00467	CbGeAlD
Methotrexate—MTHFR—liver—type 2 diabetes mellitus	0.000235	0.0046	CbGeAlD
Methotrexate—SLCO3A1—liver—type 2 diabetes mellitus	0.000231	0.00452	CbGeAlD
Methotrexate—ABCC4—kidney—type 2 diabetes mellitus	0.00023	0.00449	CbGeAlD
Methotrexate—ABCC4—pancreas—type 2 diabetes mellitus	0.000228	0.00446	CbGeAlD
Methotrexate—SLC22A8—kidney—type 2 diabetes mellitus	0.000228	0.00446	CbGeAlD
Methotrexate—ABCC4—cortex of kidney—type 2 diabetes mellitus	0.000224	0.00438	CbGeAlD
Methotrexate—ABCC2—kidney—type 2 diabetes mellitus	0.000222	0.00435	CbGeAlD
Methotrexate—SLC22A8—cortex of kidney—type 2 diabetes mellitus	0.000222	0.00434	CbGeAlD
Methotrexate—ABCC2—cortex of kidney—type 2 diabetes mellitus	0.000216	0.00424	CbGeAlD
Methotrexate—TYMS—liver—type 2 diabetes mellitus	0.000214	0.0042	CbGeAlD
Methotrexate—DHFR—liver—type 2 diabetes mellitus	0.000212	0.00415	CbGeAlD
Methotrexate—Folic Acid—CYP2E1—type 2 diabetes mellitus	0.000207	0.0785	CrCbGaD
Methotrexate—ABCC4—adipose tissue—type 2 diabetes mellitus	0.000207	0.00405	CbGeAlD
Methotrexate—PGD—liver—type 2 diabetes mellitus	0.000204	0.00399	CbGeAlD
Methotrexate—ABCC1—cortex of kidney—type 2 diabetes mellitus	0.000191	0.00373	CbGeAlD
Methotrexate—SLC16A1—liver—type 2 diabetes mellitus	0.00019	0.00373	CbGeAlD
Methotrexate—SLCO1B1—liver—type 2 diabetes mellitus	0.000185	0.00363	CbGeAlD
Methotrexate—ABCG2—nephron tubule—type 2 diabetes mellitus	0.000184	0.00361	CbGeAlD
Methotrexate—AOX1—liver—type 2 diabetes mellitus	0.00018	0.00352	CbGeAlD
Methotrexate—ABCC1—adipose tissue—type 2 diabetes mellitus	0.000176	0.00345	CbGeAlD
Methotrexate—ABCC3—liver—type 2 diabetes mellitus	0.000176	0.00344	CbGeAlD
Methotrexate—ABCC10—liver—type 2 diabetes mellitus	0.000175	0.00342	CbGeAlD
Methotrexate—SLCO1A2—liver—type 2 diabetes mellitus	0.000151	0.00295	CbGeAlD
Methotrexate—ALB—liver—type 2 diabetes mellitus	0.00015	0.00293	CbGeAlD
Methotrexate—ABCG2—adipose tissue—type 2 diabetes mellitus	0.000146	0.00286	CbGeAlD
Methotrexate—ABCC4—liver—type 2 diabetes mellitus	0.000145	0.00284	CbGeAlD
Methotrexate—ABCC2—liver—type 2 diabetes mellitus	0.00014	0.00275	CbGeAlD
Methotrexate—ABCC1—liver—type 2 diabetes mellitus	0.000124	0.00242	CbGeAlD
Methotrexate—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.000113	0.00221	CbGeAlD
Methotrexate—ABCG2—liver—type 2 diabetes mellitus	0.000102	0.00201	CbGeAlD
Methotrexate—ABCB1—retina—type 2 diabetes mellitus	9.65e-05	0.00189	CbGeAlD
Methotrexate—ABCB1—nephron tubule—type 2 diabetes mellitus	9.09e-05	0.00178	CbGeAlD
Methotrexate—ABCB1—cardiovascular system—type 2 diabetes mellitus	8.17e-05	0.0016	CbGeAlD
Methotrexate—ABCB1—kidney—type 2 diabetes mellitus	7.99e-05	0.00156	CbGeAlD
Methotrexate—ABCB1—pancreas—type 2 diabetes mellitus	7.94e-05	0.00155	CbGeAlD
Methotrexate—ABCB1—cortex of kidney—type 2 diabetes mellitus	7.78e-05	0.00152	CbGeAlD
Methotrexate—ABCB1—adipose tissue—type 2 diabetes mellitus	7.2e-05	0.00141	CbGeAlD
Methotrexate—ABCB1—liver—type 2 diabetes mellitus	5.05e-05	0.000989	CbGeAlD
Methotrexate—Nausea—Glipizide—type 2 diabetes mellitus	5.04e-05	0.000372	CcSEcCtD
Methotrexate—Vomiting—Glimepiride—type 2 diabetes mellitus	5.04e-05	0.000371	CcSEcCtD
Methotrexate—Hypotension—Valsartan—type 2 diabetes mellitus	5.04e-05	0.000371	CcSEcCtD
Methotrexate—Vision blurred—Losartan—type 2 diabetes mellitus	5.04e-05	0.000371	CcSEcCtD
Methotrexate—Vomiting—Sitagliptin—type 2 diabetes mellitus	5.02e-05	0.00037	CcSEcCtD
Methotrexate—Pain—Gliclazide—type 2 diabetes mellitus	5.02e-05	0.00037	CcSEcCtD
Methotrexate—Rash—Glimepiride—type 2 diabetes mellitus	5e-05	0.000368	CcSEcCtD
Methotrexate—Dermatitis—Glimepiride—type 2 diabetes mellitus	4.99e-05	0.000368	CcSEcCtD
Methotrexate—Rash—Sitagliptin—type 2 diabetes mellitus	4.98e-05	0.000367	CcSEcCtD
Methotrexate—Dermatitis—Sitagliptin—type 2 diabetes mellitus	4.98e-05	0.000367	CcSEcCtD
Methotrexate—Erythema multiforme—Ramipril—type 2 diabetes mellitus	4.98e-05	0.000367	CcSEcCtD
Methotrexate—Headache—Glimepiride—type 2 diabetes mellitus	4.97e-05	0.000366	CcSEcCtD
Methotrexate—Ill-defined disorder—Losartan—type 2 diabetes mellitus	4.96e-05	0.000365	CcSEcCtD
Methotrexate—Cough—Irbesartan—type 2 diabetes mellitus	4.95e-05	0.000365	CcSEcCtD
Methotrexate—Headache—Sitagliptin—type 2 diabetes mellitus	4.95e-05	0.000365	CcSEcCtD
Methotrexate—Anaemia—Losartan—type 2 diabetes mellitus	4.94e-05	0.000364	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	4.91e-05	0.000362	CcSEcCtD
Methotrexate—Tinnitus—Ramipril—type 2 diabetes mellitus	4.91e-05	0.000362	CcSEcCtD
Methotrexate—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	4.89e-05	0.000361	CcSEcCtD
Methotrexate—Infection—Metformin—type 2 diabetes mellitus	4.88e-05	0.00036	CcSEcCtD
Methotrexate—Insomnia—Valsartan—type 2 diabetes mellitus	4.88e-05	0.000359	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	4.85e-05	0.000358	CcSEcCtD
Methotrexate—Paraesthesia—Valsartan—type 2 diabetes mellitus	4.84e-05	0.000357	CcSEcCtD
Methotrexate—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	4.84e-05	0.000356	CcSEcCtD
Methotrexate—Chest pain—Irbesartan—type 2 diabetes mellitus	4.83e-05	0.000356	CcSEcCtD
Methotrexate—Myalgia—Irbesartan—type 2 diabetes mellitus	4.83e-05	0.000356	CcSEcCtD
Methotrexate—Arthralgia—Irbesartan—type 2 diabetes mellitus	4.83e-05	0.000356	CcSEcCtD
Methotrexate—Insomnia—Orlistat—type 2 diabetes mellitus	4.82e-05	0.000355	CcSEcCtD
Methotrexate—Malaise—Losartan—type 2 diabetes mellitus	4.82e-05	0.000355	CcSEcCtD
Methotrexate—Hypersensitivity—Glyburide—type 2 diabetes mellitus	4.82e-05	0.000355	CcSEcCtD
Methotrexate—Nervous system disorder—Metformin—type 2 diabetes mellitus	4.82e-05	0.000355	CcSEcCtD
Methotrexate—Thrombocytopenia—Metformin—type 2 diabetes mellitus	4.81e-05	0.000354	CcSEcCtD
Methotrexate—Dyspnoea—Valsartan—type 2 diabetes mellitus	4.81e-05	0.000354	CcSEcCtD
Methotrexate—Vertigo—Losartan—type 2 diabetes mellitus	4.8e-05	0.000354	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	4.8e-05	0.000354	CcSEcCtD
Methotrexate—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	4.8e-05	0.000354	CcSEcCtD
Methotrexate—Somnolence—Valsartan—type 2 diabetes mellitus	4.79e-05	0.000353	CcSEcCtD
Methotrexate—Paraesthesia—Orlistat—type 2 diabetes mellitus	4.78e-05	0.000353	CcSEcCtD
Methotrexate—Leukopenia—Losartan—type 2 diabetes mellitus	4.78e-05	0.000353	CcSEcCtD
Methotrexate—Discomfort—Irbesartan—type 2 diabetes mellitus	4.78e-05	0.000352	CcSEcCtD
Methotrexate—Skin disorder—Metformin—type 2 diabetes mellitus	4.77e-05	0.000352	CcSEcCtD
Methotrexate—Immune system disorder—Ramipril—type 2 diabetes mellitus	4.75e-05	0.00035	CcSEcCtD
Methotrexate—Hyperhidrosis—Metformin—type 2 diabetes mellitus	4.75e-05	0.00035	CcSEcCtD
Methotrexate—Dyspepsia—Valsartan—type 2 diabetes mellitus	4.75e-05	0.00035	CcSEcCtD
Methotrexate—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	4.74e-05	0.00035	CcSEcCtD
Methotrexate—Dizziness—Bromocriptine—type 2 diabetes mellitus	4.73e-05	0.000348	CcSEcCtD
Methotrexate—Nausea—Glimepiride—type 2 diabetes mellitus	4.71e-05	0.000347	CcSEcCtD
Methotrexate—Nausea—Sitagliptin—type 2 diabetes mellitus	4.69e-05	0.000346	CcSEcCtD
Methotrexate—Dyspepsia—Orlistat—type 2 diabetes mellitus	4.69e-05	0.000346	CcSEcCtD
Methotrexate—Asthenia—Glyburide—type 2 diabetes mellitus	4.69e-05	0.000346	CcSEcCtD
Methotrexate—Decreased appetite—Valsartan—type 2 diabetes mellitus	4.69e-05	0.000345	CcSEcCtD
Methotrexate—Anorexia—Metformin—type 2 diabetes mellitus	4.68e-05	0.000345	CcSEcCtD
Methotrexate—Cough—Losartan—type 2 diabetes mellitus	4.66e-05	0.000344	CcSEcCtD
Methotrexate—Urticaria—Gliclazide—type 2 diabetes mellitus	4.66e-05	0.000344	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	4.66e-05	0.000343	CcSEcCtD
Methotrexate—Alopecia—Ramipril—type 2 diabetes mellitus	4.65e-05	0.000343	CcSEcCtD
Methotrexate—Fatigue—Valsartan—type 2 diabetes mellitus	4.65e-05	0.000343	CcSEcCtD
Methotrexate—Abdominal pain—Gliclazide—type 2 diabetes mellitus	4.64e-05	0.000342	CcSEcCtD
Methotrexate—Body temperature increased—Gliclazide—type 2 diabetes mellitus	4.64e-05	0.000342	CcSEcCtD
Methotrexate—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	4.63e-05	0.000342	CcSEcCtD
Methotrexate—Decreased appetite—Orlistat—type 2 diabetes mellitus	4.63e-05	0.000341	CcSEcCtD
Methotrexate—Pruritus—Glyburide—type 2 diabetes mellitus	4.62e-05	0.000341	CcSEcCtD
Methotrexate—Mental disorder—Ramipril—type 2 diabetes mellitus	4.61e-05	0.00034	CcSEcCtD
Methotrexate—Infection—Irbesartan—type 2 diabetes mellitus	4.6e-05	0.000339	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	4.6e-05	0.000339	CcSEcCtD
Methotrexate—Fatigue—Orlistat—type 2 diabetes mellitus	4.59e-05	0.000339	CcSEcCtD
Methotrexate—Hypotension—Metformin—type 2 diabetes mellitus	4.59e-05	0.000338	CcSEcCtD
Methotrexate—Malnutrition—Ramipril—type 2 diabetes mellitus	4.58e-05	0.000338	CcSEcCtD
Methotrexate—Erythema—Ramipril—type 2 diabetes mellitus	4.58e-05	0.000338	CcSEcCtD
Methotrexate—Pain—Orlistat—type 2 diabetes mellitus	4.56e-05	0.000336	CcSEcCtD
Methotrexate—Myalgia—Losartan—type 2 diabetes mellitus	4.55e-05	0.000335	CcSEcCtD
Methotrexate—Arthralgia—Losartan—type 2 diabetes mellitus	4.55e-05	0.000335	CcSEcCtD
Methotrexate—Chest pain—Losartan—type 2 diabetes mellitus	4.55e-05	0.000335	CcSEcCtD
Methotrexate—Vomiting—Bromocriptine—type 2 diabetes mellitus	4.55e-05	0.000335	CcSEcCtD
Methotrexate—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	4.54e-05	0.000335	CcSEcCtD
Methotrexate—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	4.54e-05	0.000334	CcSEcCtD
Methotrexate—Rash—Bromocriptine—type 2 diabetes mellitus	4.51e-05	0.000332	CcSEcCtD
Methotrexate—Dermatitis—Bromocriptine—type 2 diabetes mellitus	4.5e-05	0.000332	CcSEcCtD
Methotrexate—Skin disorder—Irbesartan—type 2 diabetes mellitus	4.5e-05	0.000332	CcSEcCtD
Methotrexate—Discomfort—Losartan—type 2 diabetes mellitus	4.49e-05	0.000331	CcSEcCtD
Methotrexate—Dysgeusia—Ramipril—type 2 diabetes mellitus	4.49e-05	0.000331	CcSEcCtD
Methotrexate—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	4.48e-05	0.00033	CcSEcCtD
Methotrexate—Headache—Bromocriptine—type 2 diabetes mellitus	4.48e-05	0.00033	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	4.47e-05	0.00033	CcSEcCtD
Methotrexate—Diarrhoea—Glyburide—type 2 diabetes mellitus	4.47e-05	0.00033	CcSEcCtD
Methotrexate—Anorexia—Irbesartan—type 2 diabetes mellitus	4.42e-05	0.000326	CcSEcCtD
Methotrexate—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	4.41e-05	0.000325	CcSEcCtD
Methotrexate—Paraesthesia—Metformin—type 2 diabetes mellitus	4.41e-05	0.000325	CcSEcCtD
Methotrexate—Confusional state—Losartan—type 2 diabetes mellitus	4.4e-05	0.000324	CcSEcCtD
Methotrexate—Feeling abnormal—Orlistat—type 2 diabetes mellitus	4.39e-05	0.000324	CcSEcCtD
Methotrexate—Dyspnoea—Metformin—type 2 diabetes mellitus	4.38e-05	0.000323	CcSEcCtD
Methotrexate—Somnolence—Metformin—type 2 diabetes mellitus	4.37e-05	0.000322	CcSEcCtD
Methotrexate—Anaphylactic shock—Losartan—type 2 diabetes mellitus	4.36e-05	0.000321	CcSEcCtD
Methotrexate—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	4.36e-05	0.000321	CcSEcCtD
Methotrexate—Infection—Losartan—type 2 diabetes mellitus	4.33e-05	0.000319	CcSEcCtD
Methotrexate—Hypotension—Irbesartan—type 2 diabetes mellitus	4.33e-05	0.000319	CcSEcCtD
Methotrexate—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	4.32e-05	0.000319	CcSEcCtD
Methotrexate—Dyspepsia—Metformin—type 2 diabetes mellitus	4.32e-05	0.000319	CcSEcCtD
Methotrexate—Urticaria—Valsartan—type 2 diabetes mellitus	4.28e-05	0.000316	CcSEcCtD
Methotrexate—Nervous system disorder—Losartan—type 2 diabetes mellitus	4.28e-05	0.000315	CcSEcCtD
Methotrexate—Thrombocytopenia—Losartan—type 2 diabetes mellitus	4.27e-05	0.000315	CcSEcCtD
Methotrexate—Decreased appetite—Metformin—type 2 diabetes mellitus	4.27e-05	0.000315	CcSEcCtD
Methotrexate—Abdominal pain—Valsartan—type 2 diabetes mellitus	4.26e-05	0.000314	CcSEcCtD
Methotrexate—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	4.25e-05	0.000313	CcSEcCtD
Methotrexate—Nausea—Bromocriptine—type 2 diabetes mellitus	4.25e-05	0.000313	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	4.24e-05	0.000312	CcSEcCtD
Methotrexate—Fatigue—Metformin—type 2 diabetes mellitus	4.23e-05	0.000312	CcSEcCtD
Methotrexate—Urticaria—Orlistat—type 2 diabetes mellitus	4.23e-05	0.000312	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	4.22e-05	0.000311	CcSEcCtD
Methotrexate—Hyperhidrosis—Losartan—type 2 diabetes mellitus	4.22e-05	0.000311	CcSEcCtD
Methotrexate—Abdominal pain—Orlistat—type 2 diabetes mellitus	4.21e-05	0.00031	CcSEcCtD
Methotrexate—Body temperature increased—Orlistat—type 2 diabetes mellitus	4.21e-05	0.00031	CcSEcCtD
Methotrexate—Asthenia—Gliclazide—type 2 diabetes mellitus	4.21e-05	0.00031	CcSEcCtD
Methotrexate—Paraesthesia—Irbesartan—type 2 diabetes mellitus	4.16e-05	0.000307	CcSEcCtD
Methotrexate—Anorexia—Losartan—type 2 diabetes mellitus	4.16e-05	0.000306	CcSEcCtD
Methotrexate—Vomiting—Glyburide—type 2 diabetes mellitus	4.16e-05	0.000306	CcSEcCtD
Methotrexate—Pruritus—Gliclazide—type 2 diabetes mellitus	4.15e-05	0.000306	CcSEcCtD
Methotrexate—Malaise—Ramipril—type 2 diabetes mellitus	4.13e-05	0.000305	CcSEcCtD
Methotrexate—Dyspnoea—Irbesartan—type 2 diabetes mellitus	4.13e-05	0.000305	CcSEcCtD
Methotrexate—Rash—Glyburide—type 2 diabetes mellitus	4.12e-05	0.000304	CcSEcCtD
Methotrexate—Somnolence—Irbesartan—type 2 diabetes mellitus	4.12e-05	0.000304	CcSEcCtD
Methotrexate—Dermatitis—Glyburide—type 2 diabetes mellitus	4.12e-05	0.000303	CcSEcCtD
Methotrexate—Vertigo—Ramipril—type 2 diabetes mellitus	4.12e-05	0.000303	CcSEcCtD
Methotrexate—Leukopenia—Ramipril—type 2 diabetes mellitus	4.1e-05	0.000302	CcSEcCtD
Methotrexate—Headache—Glyburide—type 2 diabetes mellitus	4.09e-05	0.000302	CcSEcCtD
Methotrexate—Dyspepsia—Irbesartan—type 2 diabetes mellitus	4.08e-05	0.000301	CcSEcCtD
Methotrexate—Hypotension—Losartan—type 2 diabetes mellitus	4.08e-05	0.0003	CcSEcCtD
Methotrexate—Feeling abnormal—Metformin—type 2 diabetes mellitus	4.05e-05	0.000298	CcSEcCtD
Methotrexate—Decreased appetite—Irbesartan—type 2 diabetes mellitus	4.03e-05	0.000297	CcSEcCtD
Methotrexate—Diarrhoea—Gliclazide—type 2 diabetes mellitus	4.02e-05	0.000296	CcSEcCtD
Methotrexate—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	4.02e-05	0.000296	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	4e-05	0.000295	CcSEcCtD
Methotrexate—Cough—Ramipril—type 2 diabetes mellitus	4e-05	0.000295	CcSEcCtD
Methotrexate—Fatigue—Irbesartan—type 2 diabetes mellitus	4e-05	0.000294	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	3.97e-05	0.000293	CcSEcCtD
Methotrexate—Hypersensitivity—Valsartan—type 2 diabetes mellitus	3.97e-05	0.000293	CcSEcCtD
Methotrexate—Convulsion—Ramipril—type 2 diabetes mellitus	3.97e-05	0.000293	CcSEcCtD
Methotrexate—Pain—Irbesartan—type 2 diabetes mellitus	3.96e-05	0.000292	CcSEcCtD
Methotrexate—Insomnia—Losartan—type 2 diabetes mellitus	3.94e-05	0.000291	CcSEcCtD
Methotrexate—Hypersensitivity—Orlistat—type 2 diabetes mellitus	3.93e-05	0.000289	CcSEcCtD
Methotrexate—Paraesthesia—Losartan—type 2 diabetes mellitus	3.92e-05	0.000289	CcSEcCtD
Methotrexate—Urticaria—Metformin—type 2 diabetes mellitus	3.9e-05	0.000288	CcSEcCtD
Methotrexate—Arthralgia—Ramipril—type 2 diabetes mellitus	3.9e-05	0.000288	CcSEcCtD
Methotrexate—Chest pain—Ramipril—type 2 diabetes mellitus	3.9e-05	0.000288	CcSEcCtD
Methotrexate—Myalgia—Ramipril—type 2 diabetes mellitus	3.9e-05	0.000288	CcSEcCtD
Methotrexate—Dyspnoea—Losartan—type 2 diabetes mellitus	3.89e-05	0.000287	CcSEcCtD
Methotrexate—Nausea—Glyburide—type 2 diabetes mellitus	3.88e-05	0.000286	CcSEcCtD
Methotrexate—Abdominal pain—Metformin—type 2 diabetes mellitus	3.88e-05	0.000286	CcSEcCtD
Methotrexate—Dizziness—Gliclazide—type 2 diabetes mellitus	3.88e-05	0.000286	CcSEcCtD
Methotrexate—Somnolence—Losartan—type 2 diabetes mellitus	3.88e-05	0.000286	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	3.87e-05	0.000286	CcSEcCtD
Methotrexate—Asthenia—Valsartan—type 2 diabetes mellitus	3.87e-05	0.000285	CcSEcCtD
Methotrexate—Discomfort—Ramipril—type 2 diabetes mellitus	3.85e-05	0.000284	CcSEcCtD
Methotrexate—Dyspepsia—Losartan—type 2 diabetes mellitus	3.84e-05	0.000283	CcSEcCtD
Methotrexate—Asthenia—Orlistat—type 2 diabetes mellitus	3.82e-05	0.000282	CcSEcCtD
Methotrexate—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	3.82e-05	0.000281	CcSEcCtD
Methotrexate—Pruritus—Valsartan—type 2 diabetes mellitus	3.82e-05	0.000281	CcSEcCtD
Methotrexate—Decreased appetite—Losartan—type 2 diabetes mellitus	3.79e-05	0.000279	CcSEcCtD
Methotrexate—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	3.79e-05	0.000279	CcSEcCtD
Methotrexate—Confusional state—Ramipril—type 2 diabetes mellitus	3.77e-05	0.000278	CcSEcCtD
Methotrexate—Pruritus—Orlistat—type 2 diabetes mellitus	3.77e-05	0.000278	CcSEcCtD
Methotrexate—Fatigue—Losartan—type 2 diabetes mellitus	3.76e-05	0.000277	CcSEcCtD
Methotrexate—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	3.74e-05	0.000276	CcSEcCtD
Methotrexate—Vomiting—Gliclazide—type 2 diabetes mellitus	3.73e-05	0.000275	CcSEcCtD
Methotrexate—Pain—Losartan—type 2 diabetes mellitus	3.73e-05	0.000275	CcSEcCtD
Methotrexate—Rash—Gliclazide—type 2 diabetes mellitus	3.7e-05	0.000273	CcSEcCtD
Methotrexate—Dermatitis—Gliclazide—type 2 diabetes mellitus	3.7e-05	0.000273	CcSEcCtD
Methotrexate—Diarrhoea—Valsartan—type 2 diabetes mellitus	3.69e-05	0.000272	CcSEcCtD
Methotrexate—Urticaria—Irbesartan—type 2 diabetes mellitus	3.68e-05	0.000271	CcSEcCtD
Methotrexate—Headache—Gliclazide—type 2 diabetes mellitus	3.68e-05	0.000271	CcSEcCtD
Methotrexate—Nervous system disorder—Ramipril—type 2 diabetes mellitus	3.67e-05	0.00027	CcSEcCtD
Methotrexate—Body temperature increased—Irbesartan—type 2 diabetes mellitus	3.66e-05	0.00027	CcSEcCtD
Methotrexate—Abdominal pain—Irbesartan—type 2 diabetes mellitus	3.66e-05	0.00027	CcSEcCtD
Methotrexate—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	3.66e-05	0.00027	CcSEcCtD
Methotrexate—Diarrhoea—Orlistat—type 2 diabetes mellitus	3.65e-05	0.000269	CcSEcCtD
Methotrexate—Skin disorder—Ramipril—type 2 diabetes mellitus	3.63e-05	0.000268	CcSEcCtD
Methotrexate—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	3.62e-05	0.000266	CcSEcCtD
Methotrexate—Feeling abnormal—Losartan—type 2 diabetes mellitus	3.59e-05	0.000265	CcSEcCtD
Methotrexate—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	3.57e-05	0.000263	CcSEcCtD
Methotrexate—Dizziness—Valsartan—type 2 diabetes mellitus	3.57e-05	0.000263	CcSEcCtD
Methotrexate—Anorexia—Ramipril—type 2 diabetes mellitus	3.56e-05	0.000263	CcSEcCtD
Methotrexate—Dizziness—Orlistat—type 2 diabetes mellitus	3.52e-05	0.00026	CcSEcCtD
Methotrexate—Asthenia—Metformin—type 2 diabetes mellitus	3.52e-05	0.00026	CcSEcCtD
Methotrexate—Hypotension—Ramipril—type 2 diabetes mellitus	3.49e-05	0.000258	CcSEcCtD
Methotrexate—Nausea—Gliclazide—type 2 diabetes mellitus	3.49e-05	0.000257	CcSEcCtD
Methotrexate—Pruritus—Metformin—type 2 diabetes mellitus	3.47e-05	0.000256	CcSEcCtD
Methotrexate—Urticaria—Losartan—type 2 diabetes mellitus	3.46e-05	0.000255	CcSEcCtD
Methotrexate—Abdominal pain—Losartan—type 2 diabetes mellitus	3.45e-05	0.000254	CcSEcCtD
Methotrexate—Body temperature increased—Losartan—type 2 diabetes mellitus	3.45e-05	0.000254	CcSEcCtD
Methotrexate—Vomiting—Valsartan—type 2 diabetes mellitus	3.43e-05	0.000253	CcSEcCtD
Methotrexate—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	3.41e-05	0.000252	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	3.41e-05	0.000251	CcSEcCtD
Methotrexate—Rash—Valsartan—type 2 diabetes mellitus	3.4e-05	0.000251	CcSEcCtD
Methotrexate—Dermatitis—Valsartan—type 2 diabetes mellitus	3.4e-05	0.00025	CcSEcCtD
Methotrexate—Vomiting—Orlistat—type 2 diabetes mellitus	3.39e-05	0.00025	CcSEcCtD
Methotrexate—Insomnia—Ramipril—type 2 diabetes mellitus	3.38e-05	0.000249	CcSEcCtD
Methotrexate—Headache—Valsartan—type 2 diabetes mellitus	3.38e-05	0.000249	CcSEcCtD
Methotrexate—Diarrhoea—Metformin—type 2 diabetes mellitus	3.36e-05	0.000248	CcSEcCtD
Methotrexate—Rash—Orlistat—type 2 diabetes mellitus	3.36e-05	0.000248	CcSEcCtD
Methotrexate—Paraesthesia—Ramipril—type 2 diabetes mellitus	3.36e-05	0.000247	CcSEcCtD
Methotrexate—Dermatitis—Orlistat—type 2 diabetes mellitus	3.36e-05	0.000247	CcSEcCtD
Methotrexate—Headache—Orlistat—type 2 diabetes mellitus	3.34e-05	0.000246	CcSEcCtD
Methotrexate—Dyspnoea—Ramipril—type 2 diabetes mellitus	3.33e-05	0.000246	CcSEcCtD
Methotrexate—Asthenia—Irbesartan—type 2 diabetes mellitus	3.32e-05	0.000245	CcSEcCtD
Methotrexate—Somnolence—Ramipril—type 2 diabetes mellitus	3.32e-05	0.000245	CcSEcCtD
Methotrexate—Dyspepsia—Ramipril—type 2 diabetes mellitus	3.29e-05	0.000243	CcSEcCtD
Methotrexate—Pruritus—Irbesartan—type 2 diabetes mellitus	3.28e-05	0.000242	CcSEcCtD
Methotrexate—Decreased appetite—Ramipril—type 2 diabetes mellitus	3.25e-05	0.00024	CcSEcCtD
Methotrexate—Dizziness—Metformin—type 2 diabetes mellitus	3.25e-05	0.000239	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	3.23e-05	0.000238	CcSEcCtD
Methotrexate—Fatigue—Ramipril—type 2 diabetes mellitus	3.22e-05	0.000238	CcSEcCtD
Methotrexate—Hypersensitivity—Losartan—type 2 diabetes mellitus	3.21e-05	0.000237	CcSEcCtD
Methotrexate—Nausea—Valsartan—type 2 diabetes mellitus	3.2e-05	0.000236	CcSEcCtD
Methotrexate—Diarrhoea—Irbesartan—type 2 diabetes mellitus	3.17e-05	0.000234	CcSEcCtD
Methotrexate—Nausea—Orlistat—type 2 diabetes mellitus	3.17e-05	0.000233	CcSEcCtD
Methotrexate—Asthenia—Losartan—type 2 diabetes mellitus	3.13e-05	0.000231	CcSEcCtD
Methotrexate—Vomiting—Metformin—type 2 diabetes mellitus	3.12e-05	0.00023	CcSEcCtD
Methotrexate—Rash—Metformin—type 2 diabetes mellitus	3.1e-05	0.000228	CcSEcCtD
Methotrexate—Dermatitis—Metformin—type 2 diabetes mellitus	3.09e-05	0.000228	CcSEcCtD
Methotrexate—Pruritus—Losartan—type 2 diabetes mellitus	3.09e-05	0.000227	CcSEcCtD
Methotrexate—Feeling abnormal—Ramipril—type 2 diabetes mellitus	3.08e-05	0.000227	CcSEcCtD
Methotrexate—Headache—Metformin—type 2 diabetes mellitus	3.08e-05	0.000227	CcSEcCtD
Methotrexate—Dizziness—Irbesartan—type 2 diabetes mellitus	3.06e-05	0.000226	CcSEcCtD
Methotrexate—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	3.06e-05	0.000225	CcSEcCtD
Methotrexate—Diarrhoea—Losartan—type 2 diabetes mellitus	2.98e-05	0.00022	CcSEcCtD
Methotrexate—Urticaria—Ramipril—type 2 diabetes mellitus	2.97e-05	0.000219	CcSEcCtD
Methotrexate—Body temperature increased—Ramipril—type 2 diabetes mellitus	2.96e-05	0.000218	CcSEcCtD
Methotrexate—Abdominal pain—Ramipril—type 2 diabetes mellitus	2.96e-05	0.000218	CcSEcCtD
Methotrexate—Vomiting—Irbesartan—type 2 diabetes mellitus	2.95e-05	0.000217	CcSEcCtD
Methotrexate—Rash—Irbesartan—type 2 diabetes mellitus	2.92e-05	0.000215	CcSEcCtD
Methotrexate—Dermatitis—Irbesartan—type 2 diabetes mellitus	2.92e-05	0.000215	CcSEcCtD
Methotrexate—Nausea—Metformin—type 2 diabetes mellitus	2.92e-05	0.000215	CcSEcCtD
Methotrexate—Headache—Irbesartan—type 2 diabetes mellitus	2.9e-05	0.000214	CcSEcCtD
Methotrexate—Dizziness—Losartan—type 2 diabetes mellitus	2.88e-05	0.000213	CcSEcCtD
Methotrexate—Vomiting—Losartan—type 2 diabetes mellitus	2.77e-05	0.000204	CcSEcCtD
Methotrexate—Hypersensitivity—Ramipril—type 2 diabetes mellitus	2.76e-05	0.000203	CcSEcCtD
Methotrexate—Nausea—Irbesartan—type 2 diabetes mellitus	2.75e-05	0.000203	CcSEcCtD
Methotrexate—Rash—Losartan—type 2 diabetes mellitus	2.75e-05	0.000203	CcSEcCtD
Methotrexate—Dermatitis—Losartan—type 2 diabetes mellitus	2.75e-05	0.000202	CcSEcCtD
Methotrexate—Headache—Losartan—type 2 diabetes mellitus	2.73e-05	0.000201	CcSEcCtD
Methotrexate—Asthenia—Ramipril—type 2 diabetes mellitus	2.68e-05	0.000198	CcSEcCtD
Methotrexate—Pruritus—Ramipril—type 2 diabetes mellitus	2.65e-05	0.000195	CcSEcCtD
Methotrexate—Nausea—Losartan—type 2 diabetes mellitus	2.59e-05	0.000191	CcSEcCtD
Methotrexate—Diarrhoea—Ramipril—type 2 diabetes mellitus	2.56e-05	0.000189	CcSEcCtD
Methotrexate—Dizziness—Ramipril—type 2 diabetes mellitus	2.47e-05	0.000182	CcSEcCtD
Methotrexate—Vomiting—Ramipril—type 2 diabetes mellitus	2.38e-05	0.000175	CcSEcCtD
Methotrexate—Rash—Ramipril—type 2 diabetes mellitus	2.36e-05	0.000174	CcSEcCtD
Methotrexate—Dermatitis—Ramipril—type 2 diabetes mellitus	2.36e-05	0.000174	CcSEcCtD
Methotrexate—Headache—Ramipril—type 2 diabetes mellitus	2.34e-05	0.000173	CcSEcCtD
Methotrexate—Nausea—Ramipril—type 2 diabetes mellitus	2.22e-05	0.000164	CcSEcCtD
Methotrexate—TYMS—Metabolism—ALB—type 2 diabetes mellitus	2.26e-06	2.11e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3R1—type 2 diabetes mellitus	2.26e-06	2.11e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—NOS3—type 2 diabetes mellitus	2.26e-06	2.11e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—APOA1—type 2 diabetes mellitus	2.26e-06	2.11e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CALM1—type 2 diabetes mellitus	2.24e-06	2.09e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—APOE—type 2 diabetes mellitus	2.23e-06	2.09e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—MTHFR—type 2 diabetes mellitus	2.23e-06	2.09e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—LPL—type 2 diabetes mellitus	2.23e-06	2.08e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GLP1R—type 2 diabetes mellitus	2.23e-06	2.08e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—APOB—type 2 diabetes mellitus	2.22e-06	2.07e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—ADCY5—type 2 diabetes mellitus	2.22e-06	2.07e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—type 2 diabetes mellitus	2.21e-06	2.07e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—APOA1—type 2 diabetes mellitus	2.21e-06	2.06e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—TGFB1—type 2 diabetes mellitus	2.2e-06	2.05e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PPARA—type 2 diabetes mellitus	2.19e-06	2.05e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—LPA—type 2 diabetes mellitus	2.19e-06	2.05e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GCKR—type 2 diabetes mellitus	2.19e-06	2.05e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HSD3B2—type 2 diabetes mellitus	2.19e-06	2.05e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—KCNJ11—type 2 diabetes mellitus	2.19e-06	2.05e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—SRC—type 2 diabetes mellitus	2.19e-06	2.04e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ADCY5—type 2 diabetes mellitus	2.19e-06	2.04e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GPX1—type 2 diabetes mellitus	2.18e-06	2.03e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3R1—type 2 diabetes mellitus	2.16e-06	2.02e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—NOS3—type 2 diabetes mellitus	2.16e-06	2.02e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GSTM1—type 2 diabetes mellitus	2.16e-06	2.02e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—EGFR—type 2 diabetes mellitus	2.16e-06	2.01e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.16e-06	2.01e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GNB3—type 2 diabetes mellitus	2.16e-06	2.01e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—TGFB1—type 2 diabetes mellitus	2.15e-06	2.01e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—HMOX1—type 2 diabetes mellitus	2.15e-06	2e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	2.14e-06	2e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—AKT1—type 2 diabetes mellitus	2.12e-06	1.98e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AGT—type 2 diabetes mellitus	2.12e-06	1.98e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—LPL—type 2 diabetes mellitus	2.12e-06	1.98e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CD36—type 2 diabetes mellitus	2.12e-06	1.98e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CAT—type 2 diabetes mellitus	2.12e-06	1.98e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—EGFR—type 2 diabetes mellitus	2.11e-06	1.97e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALDOB—type 2 diabetes mellitus	2.1e-06	1.96e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PPP2CA—type 2 diabetes mellitus	2.09e-06	1.96e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CALM1—type 2 diabetes mellitus	2.09e-06	1.95e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NOS2—type 2 diabetes mellitus	2.08e-06	1.94e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SLC2A2—type 2 diabetes mellitus	2.08e-06	1.94e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PPARG—type 2 diabetes mellitus	2.08e-06	1.94e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—APOE—type 2 diabetes mellitus	2.08e-06	1.94e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ADCY5—type 2 diabetes mellitus	2.08e-06	1.94e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ALB—type 2 diabetes mellitus	2.07e-06	1.94e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IGF1—type 2 diabetes mellitus	2.07e-06	1.93e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GPX1—type 2 diabetes mellitus	2.07e-06	1.93e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—AKT2—type 2 diabetes mellitus	2.07e-06	1.93e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTGS2—type 2 diabetes mellitus	2.06e-06	1.93e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—APOB—type 2 diabetes mellitus	2.06e-06	1.92e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—APOA1—type 2 diabetes mellitus	2.06e-06	1.92e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—INS—type 2 diabetes mellitus	2.04e-06	1.9e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—MTR—type 2 diabetes mellitus	2.04e-06	1.9e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CPT1A—type 2 diabetes mellitus	2.04e-06	1.9e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CD36—type 2 diabetes mellitus	2.02e-06	1.88e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—MTHFR—type 2 diabetes mellitus	2.01e-06	1.88e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	2e-06	1.87e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GSTM1—type 2 diabetes mellitus	2e-06	1.87e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NAMPT—type 2 diabetes mellitus	2e-06	1.87e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IRS1—type 2 diabetes mellitus	1.99e-06	1.86e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.99e-06	1.86e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	1.99e-06	1.86e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—LIPC—type 2 diabetes mellitus	1.99e-06	1.85e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HBA1—type 2 diabetes mellitus	1.99e-06	1.85e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GCK—type 2 diabetes mellitus	1.99e-06	1.85e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3R1—type 2 diabetes mellitus	1.98e-06	1.85e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—NOS3—type 2 diabetes mellitus	1.98e-06	1.85e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTGS2—type 2 diabetes mellitus	1.98e-06	1.85e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP11A1—type 2 diabetes mellitus	1.97e-06	1.84e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PPARA—type 2 diabetes mellitus	1.97e-06	1.84e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—SERPINE1—type 2 diabetes mellitus	1.97e-06	1.84e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—LPL—type 2 diabetes mellitus	1.96e-06	1.83e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—TGFB1—type 2 diabetes mellitus	1.96e-06	1.83e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GLP1R—type 2 diabetes mellitus	1.95e-06	1.82e-05	CbGpPWpGaD
Methotrexate—PGD—Metabolism—AKT1—type 2 diabetes mellitus	1.94e-06	1.81e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SLC9A1—type 2 diabetes mellitus	1.94e-06	1.81e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ADCY5—type 2 diabetes mellitus	1.92e-06	1.8e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—EGFR—type 2 diabetes mellitus	1.92e-06	1.79e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GPX1—type 2 diabetes mellitus	1.92e-06	1.79e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CETP—type 2 diabetes mellitus	1.92e-06	1.79e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—MTHFR—type 2 diabetes mellitus	1.91e-06	1.78e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AGT—type 2 diabetes mellitus	1.91e-06	1.78e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—INS—type 2 diabetes mellitus	1.91e-06	1.78e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—AKT1—type 2 diabetes mellitus	1.91e-06	1.78e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	1.88e-06	1.75e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CALM1—type 2 diabetes mellitus	1.88e-06	1.75e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—NOS3—type 2 diabetes mellitus	1.88e-06	1.75e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3R1—type 2 diabetes mellitus	1.88e-06	1.75e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PPARA—type 2 diabetes mellitus	1.87e-06	1.75e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—APOE—type 2 diabetes mellitus	1.87e-06	1.75e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ALB—type 2 diabetes mellitus	1.87e-06	1.75e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CD36—type 2 diabetes mellitus	1.87e-06	1.74e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—APOA1—type 2 diabetes mellitus	1.85e-06	1.73e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT2—type 2 diabetes mellitus	1.85e-06	1.72e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PPP2CA—type 2 diabetes mellitus	1.84e-06	1.72e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC2A2—type 2 diabetes mellitus	1.82e-06	1.7e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AGT—type 2 diabetes mellitus	1.82e-06	1.69e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTGS2—type 2 diabetes mellitus	1.81e-06	1.69e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PPARG—type 2 diabetes mellitus	1.81e-06	1.69e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3R1—type 2 diabetes mellitus	1.79e-06	1.67e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—NOS3—type 2 diabetes mellitus	1.79e-06	1.67e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CPT1A—type 2 diabetes mellitus	1.79e-06	1.67e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—MTR—type 2 diabetes mellitus	1.79e-06	1.67e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CALM1—type 2 diabetes mellitus	1.78e-06	1.67e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PSMD6—type 2 diabetes mellitus	1.78e-06	1.66e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SREBF1—type 2 diabetes mellitus	1.78e-06	1.66e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SNAP25—type 2 diabetes mellitus	1.78e-06	1.66e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—APOE—type 2 diabetes mellitus	1.78e-06	1.66e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—INS—type 2 diabetes mellitus	1.78e-06	1.66e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—MTHFR—type 2 diabetes mellitus	1.77e-06	1.65e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—APOA1—type 2 diabetes mellitus	1.76e-06	1.64e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SERPINE1—type 2 diabetes mellitus	1.75e-06	1.64e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NAMPT—type 2 diabetes mellitus	1.75e-06	1.63e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CTGF—type 2 diabetes mellitus	1.75e-06	1.63e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HBA1—type 2 diabetes mellitus	1.74e-06	1.62e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—LIPC—type 2 diabetes mellitus	1.74e-06	1.62e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GCK—type 2 diabetes mellitus	1.74e-06	1.62e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PPARA—type 2 diabetes mellitus	1.74e-06	1.62e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HMGCR—type 2 diabetes mellitus	1.73e-06	1.62e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP11A1—type 2 diabetes mellitus	1.73e-06	1.61e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	1.71e-06	1.6e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC9A1—type 2 diabetes mellitus	1.7e-06	1.59e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ADRA2A—type 2 diabetes mellitus	1.7e-06	1.58e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AGT—type 2 diabetes mellitus	1.68e-06	1.57e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CETP—type 2 diabetes mellitus	1.68e-06	1.57e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—AKT1—type 2 diabetes mellitus	1.67e-06	1.56e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NOS3—type 2 diabetes mellitus	1.67e-06	1.56e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3R1—type 2 diabetes mellitus	1.67e-06	1.56e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—IL6—type 2 diabetes mellitus	1.66e-06	1.55e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CALM1—type 2 diabetes mellitus	1.65e-06	1.54e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—type 2 diabetes mellitus	1.65e-06	1.54e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—APOE—type 2 diabetes mellitus	1.65e-06	1.54e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTGS2—type 2 diabetes mellitus	1.64e-06	1.53e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PPARG—type 2 diabetes mellitus	1.63e-06	1.52e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP2E1—type 2 diabetes mellitus	1.63e-06	1.52e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ALB—type 2 diabetes mellitus	1.63e-06	1.52e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—APOA1—type 2 diabetes mellitus	1.63e-06	1.52e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—IL6—type 2 diabetes mellitus	1.62e-06	1.51e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SLC2A1—type 2 diabetes mellitus	1.61e-06	1.5e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP1A2—type 2 diabetes mellitus	1.61e-06	1.5e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—INS—type 2 diabetes mellitus	1.6e-06	1.49e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP3A4—type 2 diabetes mellitus	1.57e-06	1.47e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	1.56e-06	1.46e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PSMD6—type 2 diabetes mellitus	1.56e-06	1.46e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SREBF1—type 2 diabetes mellitus	1.56e-06	1.46e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SNAP25—type 2 diabetes mellitus	1.56e-06	1.46e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	1.56e-06	1.45e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—NOS3—type 2 diabetes mellitus	1.56e-06	1.45e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PPARG—type 2 diabetes mellitus	1.55e-06	1.45e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GCG—type 2 diabetes mellitus	1.54e-06	1.44e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SLC2A4—type 2 diabetes mellitus	1.54e-06	1.44e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CTGF—type 2 diabetes mellitus	1.53e-06	1.43e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTGS2—type 2 diabetes mellitus	1.53e-06	1.43e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—AKT1—type 2 diabetes mellitus	1.53e-06	1.43e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—INS—type 2 diabetes mellitus	1.52e-06	1.42e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HMGCR—type 2 diabetes mellitus	1.52e-06	1.42e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—AKT1—type 2 diabetes mellitus	1.49e-06	1.4e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	1.49e-06	1.39e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ADRA2A—type 2 diabetes mellitus	1.49e-06	1.39e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—IL6—type 2 diabetes mellitus	1.47e-06	1.38e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ALB—type 2 diabetes mellitus	1.47e-06	1.37e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PPARG—type 2 diabetes mellitus	1.43e-06	1.34e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP2E1—type 2 diabetes mellitus	1.43e-06	1.33e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTGS2—type 2 diabetes mellitus	1.43e-06	1.33e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP1A2—type 2 diabetes mellitus	1.41e-06	1.32e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC2A1—type 2 diabetes mellitus	1.41e-06	1.32e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—INS—type 2 diabetes mellitus	1.41e-06	1.31e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.4e-06	1.31e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—NOS3—type 2 diabetes mellitus	1.4e-06	1.31e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ALB—type 2 diabetes mellitus	1.39e-06	1.3e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—SRC—type 2 diabetes mellitus	1.39e-06	1.3e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP3A4—type 2 diabetes mellitus	1.38e-06	1.29e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—AKT1—type 2 diabetes mellitus	1.36e-06	1.27e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC2A4—type 2 diabetes mellitus	1.35e-06	1.26e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GCG—type 2 diabetes mellitus	1.35e-06	1.26e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—type 2 diabetes mellitus	1.35e-06	1.26e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.33e-06	1.24e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—NOS3—type 2 diabetes mellitus	1.33e-06	1.24e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GNB3—type 2 diabetes mellitus	1.33e-06	1.24e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.33e-06	1.24e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HMOX1—type 2 diabetes mellitus	1.33e-06	1.24e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CAT—type 2 diabetes mellitus	1.31e-06	1.22e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ALB—type 2 diabetes mellitus	1.29e-06	1.2e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTGS2—type 2 diabetes mellitus	1.28e-06	1.2e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—AKT1—type 2 diabetes mellitus	1.28e-06	1.2e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—APOB—type 2 diabetes mellitus	1.27e-06	1.19e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—AKT1—type 2 diabetes mellitus	1.25e-06	1.17e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TGFB1—type 2 diabetes mellitus	1.24e-06	1.16e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SRC—type 2 diabetes mellitus	1.24e-06	1.16e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTM1—type 2 diabetes mellitus	1.24e-06	1.15e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—NOS3—type 2 diabetes mellitus	1.23e-06	1.15e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3R1—type 2 diabetes mellitus	1.23e-06	1.15e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTGS2—type 2 diabetes mellitus	1.22e-06	1.14e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—LPL—type 2 diabetes mellitus	1.21e-06	1.13e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ADCY5—type 2 diabetes mellitus	1.19e-06	1.11e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GPX1—type 2 diabetes mellitus	1.18e-06	1.1e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	1.17e-06	1.09e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.17e-06	1.09e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	1.16e-06	1.08e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CD36—type 2 diabetes mellitus	1.15e-06	1.08e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	1.15e-06	1.07e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—AKT1—type 2 diabetes mellitus	1.14e-06	1.06e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PPP2CA—type 2 diabetes mellitus	1.14e-06	1.06e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTGS2—type 2 diabetes mellitus	1.13e-06	1.05e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	1.11e-06	1.04e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TGFB1—type 2 diabetes mellitus	1.11e-06	1.03e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—MTHFR—type 2 diabetes mellitus	1.09e-06	1.02e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGFR—type 2 diabetes mellitus	1.09e-06	1.01e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	1.08e-06	1.01e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PPARA—type 2 diabetes mellitus	1.07e-06	1e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	1.06e-06	9.91e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	1.04e-06	9.71e-06	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—AKT1—type 2 diabetes mellitus	1.04e-06	9.68e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AGT—type 2 diabetes mellitus	1.04e-06	9.68e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	1.04e-06	9.67e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CALM1—type 2 diabetes mellitus	1.02e-06	9.52e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—APOE—type 2 diabetes mellitus	1.02e-06	9.48e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	1.01e-06	9.42e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—APOA1—type 2 diabetes mellitus	1e-06	9.38e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	9.97e-07	9.3e-06	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—AKT1—type 2 diabetes mellitus	9.94e-07	9.28e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	9.56e-07	8.93e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	9.38e-07	8.76e-06	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AKT1—type 2 diabetes mellitus	9.12e-07	8.51e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	9.09e-07	8.48e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	8.93e-07	8.34e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	8.9e-07	8.31e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PPARG—type 2 diabetes mellitus	8.85e-07	8.26e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	8.8e-07	8.22e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—INS—type 2 diabetes mellitus	8.68e-07	8.1e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—AKT1—type 2 diabetes mellitus	8.63e-07	8.06e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IL6—type 2 diabetes mellitus	8.34e-07	7.79e-06	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AKT1—type 2 diabetes mellitus	8.23e-07	7.68e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	7.76e-07	7.24e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT1—type 2 diabetes mellitus	7.7e-07	7.18e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3R1—type 2 diabetes mellitus	7.61e-07	7.11e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NOS3—type 2 diabetes mellitus	7.61e-07	7.11e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—INS—type 2 diabetes mellitus	7.61e-07	7.1e-06	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AKT1—type 2 diabetes mellitus	7.16e-07	6.69e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	6.97e-07	6.51e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS2—type 2 diabetes mellitus	6.96e-07	6.5e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	6.67e-07	6.23e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	6.67e-07	6.23e-06	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AKT1—type 2 diabetes mellitus	6.45e-07	6.02e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AKT1—type 2 diabetes mellitus	6.12e-07	5.72e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	6.1e-07	5.69e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKT1—type 2 diabetes mellitus	5.67e-07	5.29e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKT1—type 2 diabetes mellitus	3.5e-07	3.27e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	3.07e-07	2.86e-06	CbGpPWpGaD
